Friday 22 November 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
New show of faith in microbiome with EnteroBiotix financing
7 September 2021
Biotechnology
Third clinical program bought by AI-based microbiome specialist
27 April 2022
Biotechnology
Seres Therapeutics falls despite positive Phase III results with SER-109
24 May 2022
Biotechnology
MaaT Pharma partners with Skyepharma on microbiome production
9 February 2022


Companies featured in this story

More ones to watch >


Today's issue

Takeda launches Fruzaqla in Japan
Biotechnology
Takeda launches Fruzaqla in Japan
22 November 2024
Biotechnology
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
Biotechnology
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Biotechnology
Paragon Therapeutics appoints first chief executive
22 November 2024
Pharmaceutical
Pfizer to help commercialize Xacduro in China
22 November 2024
Pharmaceutical
Amid RFK Jr vaccine worries, FDA’s Peter Marks remains calm
22 November 2024
Biotechnology
Versant Ventures unveils obesity focused Pep2Tango Therapeutics
22 November 2024

Company Spotlight

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.




More Features in Biotechnology

Takeda launches Fruzaqla in Japan
22 November 2024
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Paragon Therapeutics appoints first chief executive
22 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze